The Trial of Continuous Intravenous Infusion of Magnesium in Patients with Postherpetic Neuralgia Refractory in Conventional Treatment: A report of 2 cases.
10.4097/kjae.2006.50.3.361
- Author:
Yong Kwan CHEONG
1
;
Tai Yo KIM
;
Ju Hwan LEE
Author Information
1. Department of Anesthesiology and Pain Medicine, School of Medicine, Wonkwang University, Iksan, Korea. ykfolder@naver.com
- Publication Type:Case Report
- Keywords:
magnesium;
neuropathic pain;
NMDA receptor antagonist;
postherpetic neuralgia
- MeSH:
Calcium;
Humans;
Hyperalgesia;
Infusions, Intravenous*;
Ion Channels;
Ions;
Magnesium*;
N-Methylaspartate;
Neuralgia;
Neuralgia, Postherpetic*;
Neurons;
Pain Clinics
- From:Korean Journal of Anesthesiology
2006;50(3):361-364
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Postherpetic neuralgia is one of the most troublesome diseases in pain clinics. The N-methyl-D-aspartate (NMDA) receptor antagonist, magnesium, reduces the level of neuropathic pain and hyperalgesia in patients with postherpetic neuralgia. Magnesium has been shown to exert a physiological block of the ion channel on the NMDA receptor, thereby preventing extracellular calcium ions from entering the cell and contributing to secondary neuronal changes. Accordingly, we attempted to administer a continuous intravenous infusion of magnesium, which resulted in a decrease in the VAS without side effects.
